Life after acquisition? Heptares CEO on living with Sosei
This article was originally published in Scrip
Heptares, a structure-based drug design specialist, was one of the shinier jewels in the UK biotech crown prior to its $400m acquisition by Sosei earlier this year. CEO and chairman Malcolm Weir, who hung on to his position and even added executive vice president and chief R&D officer at Sosei to his job title, spoke to Scrip about how life has changed after being swallowed up by a Japanese pharma company, and highlights from a recent R&D day in Japan.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.